Biotechnology News

~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse...

WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)...

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with...

Nu-Tek BioSciences attends CPhI Worldwide in Milan Oct 6-8, 2026

Nu-Tek viendra à la rencontre des acteurs du secteur pharmaceutique lors du salon CPHI Global, qui se tiendra du 6 au 8 octobre à Milan, afin de présenter ses peptones et hydrolysats de protéines...

Nu-Tek wird auf der CPHI Global vom 6. bis 8. Oktober in Mailand mit Akteuren aus der Pharmabranche ins Gespräch kommen, um seine zu 100 % tierfreien Peptone und Proteinhydrolysate vorzustellen, die...

MILAN, Italy and MORRISTOWN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of...

LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will...

TOKYO and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the National Medical Products Administration (NMPA) of China has...

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés...